Evidence map›Paper›PMID 38203786›Full record

ArticleInternational journal of molecular sciences2024

Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer.

Mira Ebbinghaus, Katharina Wittich, Benjamin Bancher, Valeriia Lebedeva, Anijutta Appelshoffer, Julia Femel, Martin S Helm, Jutta Kollet, Olaf Hardt, Rita Pfeifer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mira EbbinghausMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Katharina WittichMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Benjamin BancherMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Valeriia LebedevaMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0001-7171-4789
Anijutta AppelshofferMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Julia FemelMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Martin S HelmMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0002-6217-911X
Jutta KolletMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Olaf HardtMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0003-0825-071X
Rita PfeiferMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.

Funding

European Union's Horizon 2020 860003LeitmarktAgentur.NRW LS-2-2-050
6 · The paper itself

Abstract

As chimeric antigen receptor (CAR) T cell therapy continues to gain attention as a valuable treatment option against different cancers, strategies to improve its potency and decrease the side effects associated with this therapy have become increasingly relevant. Herein, we report an alternative CAR design that incorporates transmembrane domains with the ability to recruit endogenous signaling molecules, eliminating the need for stimulatory signals within the CAR structure. These endogenous signaling molecule activating (ESMA) CARs triggered robust cytotoxic activity and proliferation of the T cells when directed against the triple-negative breast cancer (TNBC) cell line MDA-MB-231 while exhibiting reduced cytokine secretion and exhaustion marker expression compared to their cognate standard second generation CARs. In a

Indexed as

Triple Negative Breast NeoplasmsAnimalsCell LineDisease Models, AnimalGamma RaysHumansMiceMice, SCIDalternative CAR signalingCAR T cellsendogenous CAR signaling mechanismsimmunofluorescent imagingin vivo studiessolid tumorsT cell exhaustionT cell persistencetriple-negative breast cancer

Identifiers

PMID38203786
PMCPMC10779313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.